Pelletier J P, McCollum R, Cloutier J M, Martel-Pelletier J
Rheumatic Disease Unit, Notre Dame Hospital Research Centre, Montréal, Québec, Canada.
Br J Rheumatol. 1992;31 Suppl 1:19-26.
The effect of therapeutic and pharmacological concentrations of tiaprofenic acid, a non-steroidal anti-inflammatory drug (NSAID), on the synthesis of the plasminogen activators, urokinase plasminogen activator (uPA) and tissue plasminogen activator (tPA), and the plasminogen activator inhibitors 1 and 2 (PAI-1 and PAI-2), by human synovial membranes isolated from osteoarthritis (OA) and rheumatoid arthritis (RA) sufferers was evaluated. Both forms of plasminogen activator (PA) and PA inhibitor (PAI) were synthesized by the arthritic synovium. PAI-1 and PAI-2 were both synthesized in greater amounts than the plasminogen activators. Tiaprofenic acid induced a dose-dependent decrease in uPA synthesis in both OA and RA, particularly in OA synovium, but had no true effect on tPA. Tiaprofenic acid also exerted a suppressive effect on the synthesis of PAI-1 in both OA and RA synovial membranes, and on the release of PAI-2 in RA synovium. The results of this study indicate that a decrease in uPA synthesis may be one of the mechanisms by which tiaprofenic acid could exert its effects on the arthritic process. The suppressive action of tiaprofenic acid on PAI is not likely to have a significant impact on the balance of plasminogen activators and plasminogen activator inhibitors, as plasminogen activator inhibitors are synthesized in greater amounts than plasminogen activators.
评估了非甾体抗炎药(NSAID)噻洛芬酸的治疗浓度和药理浓度对从骨关节炎(OA)和类风湿关节炎(RA)患者分离出的人滑膜合成纤溶酶原激活剂、尿激酶型纤溶酶原激活剂(uPA)和组织型纤溶酶原激活剂(tPA)以及纤溶酶原激活剂抑制剂1和2(PAI-1和PAI-2)的影响。两种形式的纤溶酶原激活剂(PA)和PA抑制剂(PAI)均由关节炎滑膜合成。PAI-1和PAI-2的合成量均高于纤溶酶原激活剂。噻洛芬酸在OA和RA中均诱导uPA合成呈剂量依赖性下降,在OA滑膜中尤为明显,但对tPA无实际影响。噻洛芬酸对OA和RA滑膜中PAI-1的合成以及RA滑膜中PAI-2的释放也有抑制作用。本研究结果表明,uPA合成减少可能是噻洛芬酸对关节炎进程发挥作用的机制之一。噻洛芬酸对PAI的抑制作用不太可能对纤溶酶原激活剂和纤溶酶原激活剂抑制剂的平衡产生显著影响,因为纤溶酶原激活剂抑制剂的合成量高于纤溶酶原激活剂。